FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to use of pyrrolidone-carboxylic acid (PCA) and/or pharmaceutically acceptable salts thereof for treating eye diseases and/or disorders, selected from eye dryness, hyperosmolarity of eyes, eye inflammations and/or eye injections and blepharitis.
EFFECT: this enables higher clinical effectiveness in both adults and children, due to optimal characteristics of physical and chemical stability of pharmaceutical composition with its long time of preservation in eye tissues and no side effects.
9 cl, 1 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SULGLYCOTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT FOR PREVENTING OR TREATING DRY EYES SYNDROME | 2018 |
|
RU2722485C1 |
| OPHTHALMIC COMPOSITION | 2017 |
|
RU2749723C2 |
| COMPOUNDS FOR TREATING/PREVENTING INFLAMMATORY OPHTHALMIC DISEASES | 2011 |
|
RU2582609C2 |
| GEL-LIKE ARTIFICIAL TEARS WITH ANTISEPTIC AND REPARATIVE ACTION | 2018 |
|
RU2679319C1 |
| OPHTHALMIC COMPOSITIONS OF TAMARIND SEED POLYSACCHARIDE AND HYALURONIC ACID | 2008 |
|
RU2493855C2 |
| CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS FOR PREPARATION AND METHODS FOR USE THEREOF | 2012 |
|
RU2602062C2 |
| COMPOSITIONS AND METHODS FOR JAK PATH INHIBITION | 2010 |
|
RU2557982C2 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
| EYE DROPS FOR TREATING DRY EYE SYNDROME | 2006 |
|
RU2302231C1 |
| COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS | 2019 |
|
RU2792627C2 |
